Compare PPL Corporation Common Stock (PPL) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPL Corporation Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? PPL Corporation Common Stock trades at $34.75 (market cap $26.06B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: PPL Corporation Common Stock is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and PPL Corporation Common Stock pays a 3.29% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPL Corporation Common Stock for 5 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PPL | SYRE | |
|---|---|---|
Market Cap | $26.06B | $7.52B |
Volume | 5,432,693 | 1,441,031 |
Sector | Utilities | Health |
52-Week High | $39.81 | $108.92 |
52-Week Low | $31.97 | $22.18 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $46.05B | $6.52B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPL Corporation trades at $34.63, up 0.84% with a bullish technical outlook supported by moving averages. The utility company shows solid fundamentals with $9.04B revenue, 13.47% net margin, and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $39.45 price target, representing 14% upside potential from current levels. Recent news highlights PPL's $23B infrastructure investment plan and focus on meeting rising electricity demand through strategic capacity expansion.
PPL presents a compelling investment case with strong analyst support, dividend growth potential, and strategic positioning in the growing utility sector. Key risks include execution challenges from the massive capital expenditure program, regulatory hurdles, and competitive pressures. The stock's current valuation at 20.49 P/E appears reasonable given the company's growth trajectory and defensive characteristics in the utility space.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PPL Corporation Common Stock
PPL Corporation is a regulated utility holding company. Through its subsidiaries, it generates, transmits, distributes, and sells electricity and natural gas in Kentucky, Pennsylvania, and Rhode Island.
Read more on PPL →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
